Alaunos Therapeutics, Inc. Repayments of Long-Term Debt
Alaunos Therapeutics, Inc. (TCRT) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2025-03-31
- Alaunos Therapeutics, Inc. repayments of long-term debt for the quarter ending 2024-12-31 was $0.00.
- Alaunos Therapeutics, Inc. repayments of long-term debt for the quarter ending 2024-09-30 was $0.00.
- Alaunos Therapeutics, Inc. repayments of long-term debt for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. repayments of long-term debt for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. repayments of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. repayments of long-term debt for fiscal 2023 was $18.11M, a 117.27% increase from fiscal 2022.
- Alaunos Therapeutics, Inc. repayments of long-term debt for fiscal 2022 was $8.33M.
- Alaunos Therapeutics, Inc. repayments of long-term debt for fiscal 2021 was $0.00.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $11.86M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $11.86M derived: sum of 3 quarters · filed 2025-03-31 | $18.11M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $11.86M derived: sum of 2 quarters · filed 2024-11-14 | $18.11M 10-Q · filed 2024-11-14 | $24.36M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $11.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $18.11M 10-Q · filed 2024-08-14 | $24.36M derived: sum of 3 quarters · filed 2024-08-14 | $26.44M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $6.25M 10-Q · filed 2024-05-15 | $12.50M derived: sum of 2 quarters · filed 2024-05-15 | $14.58M derived: sum of 3 quarters · filed 2024-05-15 | $14.58M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $8.33M derived: sum of 2 quarters · filed 2024-04-01 | $8.33M derived: sum of 3 quarters · filed 2024-04-01 | $8.33M 10-K · filed 2024-04-01 |
| 2022-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.08M derived: sum of 2 quarters · filed 2023-11-14 | $2.08M 10-Q · filed 2023-11-14 | $2.08M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |